深圳瑞华泰薄膜科技股份有限公司 股东会议事规则 第一章 总则 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体 董事应当勤勉尽责，确保股东会正常召开和依法行使职权。 公司在上述期限内不能召开股东会的，应当报告公司所在地中国证 券监督管理委员会（以下简称"中国证监会"）派出机构和公司股 票挂牌交易的证券交易所（以下简称"证券交易所"），说明原因 并公告。 第五条 公司召开股东会，应当聘请律师对以下问题出具法律意见并公告： (一)会议的召集、召开程序是否符合法律、行政法规、本规则和公司 章程的规定； 1 / 10 第一条 为促进公司规范运作，提高股东会议事效率，保障股东合法权益，保 证大会程序及决议内容的合法有效性，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）公司章程等有关规定，结合公司实际情况， 制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 第三条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召 ...

| | | 深圳瑞华泰薄膜科技股份有限公司 关于取消监事会、调整董事会人数、修订《公司章 程》及修订、制定公司部分管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）于 2025 年 7 月 24 日召开了第三届董事会第三次会议，审议通过了《关于取消监事会、调整董事会 人数、修订<公司章程>并办理工商变更登记的议案》《关于修订及制定公司部分 治理制度的议案》，具体情况如下： 一、取消监事会、调整董事会人数的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章程指 引》等法律、法规及规范性文件的规定，结合公司实际情况，公司将不再设置监 事会，监事会的职权由董事会审计委员会行使，同时，《监事会议事规则》相应 废止，公司各项规章制度中涉及监事会、监事的规定不再适用。另外，为提高公 司董事会运作效率和科学决策水平，优化公司法人治理结构，公司拟将董事会成 员人数由 7 名调整为 8 名，其中独立董事 3 名，非独立董事 4 名，职工代表董事 1 名。 ...

| 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-033 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 深圳瑞华泰薄膜科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 召开日期时间：2025 年 8 月 19 日 14 点 30 分 召开地点：深圳市宝安区松岗街道办华美工业园深圳瑞华泰薄膜科技股份有 限公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 19 日 股东大会召开日期：2025年8月19日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is a pioneer in the domestic substitution of optical OCA glue, with revenue expected to continue growing significantly. In 2024, the company's electronic-grade adhesive materials are projected to generate 1.43 billion yuan, a year-on-year increase of 66%, primarily driven by OCA optical glue [9] - The company is accelerating vertical integration to build a comprehensive supply chain, achieving over 70% self-sufficiency in key materials for OCA optical glue. This integrated approach is expected to enhance profitability as the scale effect materializes [9] - Profitability is currently under pressure due to prior investments, but profits are anticipated to grow rapidly after the peak of depreciation costs passes [9] Financial Forecasts and Investment Recommendations - The company is forecasted to achieve net profits attributable to the parent company of 141 million yuan, 275 million yuan, and 439 million yuan for the years 2025 to 2027, respectively. This is an adjustment from previous forecasts due to a downward revision in gross margin and an upward revision in revenue [3][10] - The target price is set at 19.52 yuan based on a comparable company PE of 32 times for 2026 [3][10] - Revenue projections for the company are as follows: 1,969 million yuan in 2023, 2,691 million yuan in 2024, 3,535 million yuan in 2025, 4,431 million yuan in 2026, and 5,345 million yuan in 2027, reflecting a compound annual growth rate of 20.6% from 2025 to 2027 [5][11]

| | | 深圳瑞华泰薄膜科技股份有限公司 关于"瑞科转债"预计满足转股价格修正条件 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债发行上市概况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意深圳瑞华 泰薄膜科技股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监 许可〔2022〕1546 号）同意注册，深圳瑞华泰薄膜科技股份有限公司（以下简 称"公司"）于 2022 年 8 月 18 日向不特定对象共计发行 430 万张可转换公司债 券（以下简称"可转债"），每张面值为人民币 100 元，按面值发行，本次发行总 额为人民币 43,000.00 万元，可转债期限为自发行之日起六年。 上述方案须经出席会议的股东所持表决权的三分之二以上通过方可实施。股 东大会进行表决时，持有本次发行的可转债的股东应当回避。修正后的转股价格 应不低于本次股东大会召开日前二十个交易日公司股票交易均价和前一个交易 日公司股票交易均价。 2、修正程序 如公司决定向下修正转股价格时，公司将在上交所网站（w ...

Core Viewpoint - The event highlighted Shenzhen's strategic focus on developing the high-performance materials industry, emphasizing its role in enhancing the manufacturing sector and seizing future industrial opportunities [1][3]. Group 1: Industry Development - Shenzhen's Industrial and Information Technology Bureau emphasizes the importance of high-performance materials as a key area for consolidating manufacturing advantages and capturing future industrial leadership [1]. - The event showcased Shenzhen's unique advantages in electronic information materials and high-end chemical products, providing forward-looking development suggestions for participating companies [1][2]. Group 2: Infrastructure and Investment - The Shenzhen Chemical Park is being developed with international standards focusing on integrated circuits and new energy materials, offering comprehensive support services for enterprises [2]. - Local leading enterprises shared successful experiences, highlighting the strong support from Shenzhen's innovation ecosystem for technological breakthroughs [2]. Group 3: Collaboration and Networking - The event facilitated discussions among representatives from various companies, exploring opportunities for technological cooperation and investment [2]. - The Secretary-General of the Shenzhen New Materials Industry Association called for global entrepreneurs, scientists, and investors to collaborate with Shenzhen, leveraging the benefits of the Guangdong-Hong Kong-Macao Greater Bay Area [2][3].

Core Viewpoint - Haichuang Pharmaceutical Co., Ltd. has launched its self-developed innovative anti-cancer drug, Dihydro-Enzalutamide soft capsule, marking a significant milestone in its development journey [2][3] Group 1: Product Launch and Clinical Significance - Dihydro-Enzalutamide soft capsule is recognized as a new type of androgen receptor antagonist (ARi) and has shown significant clinical value, particularly in treating metastatic castration-resistant prostate cancer (mCRPC) [2] - Clinical studies indicate that Dihydro-Enzalutamide significantly improves disease progression and survival rates while demonstrating excellent safety profiles, with no adverse events such as falls or seizures reported [2] - Experts suggest that Dihydro-Enzalutamide has the potential to be moved forward in treatment protocols for metastatic hormone-sensitive prostate cancer (mHSPC) [2][3] Group 2: Company Development and Future Plans - The inauguration of Haichuang Pharmaceutical's headquarters and the rapid nationwide supply of Dihydro-Enzalutamide signify a critical leap from research innovation to industrial empowerment [3] - The company focuses on developing innovative drugs for cancer and metabolic diseases and plans to accelerate the global rollout of multiple anti-cancer and metabolic disease drugs [3] - Haichuang Pharmaceutical's chairman emphasized the importance of patient-centered research and the collective effort of employees and partners in achieving this milestone [3]

Core Viewpoint - The article emphasizes the urgency of domestic substitution for "choke point" technologies in various industries due to escalating Sino-US trade tensions and the need for self-sufficiency in critical sectors [2][3]. Group 1: Research Framework & Key Industries - A comprehensive research framework is established, focusing on ten key industries: electronics, computers, communications, pharmaceuticals, medical, automotive, machinery, military, metals, and chemicals [3]. - The framework combines top-down and bottom-up approaches to assess the current state, challenges, and prospects of domestic substitution in these industries [3]. Group 2: Key Areas of Domestic Substitution - The report identifies 41 categories of critical technologies for domestic substitution across the ten industries, highlighting the importance of these areas for attracting investment [2][3]. - The analysis categorizes the difficulty of domestic substitution into five levels, ranging from extremely difficult to easy, based on factors such as market share and technological barriers [8][11]. Group 3: Electronics Industry - The semiconductor sector is highlighted as a key area for domestic substitution, with a focus on storage chips, CPUs, and GPUs, where current domestic market shares are below 5% [11][14]. - The article notes that the government is expected to increase support for key technologies in the semiconductor industry, particularly in overcoming manufacturing and equipment limitations [14][15]. Group 4: Computer Industry - The article discusses the development of a self-controlled IT ecosystem driven by policies aimed at enhancing domestic capabilities in hardware and software [19][20]. - The industrial software market is identified as a significant area for growth, with domestic companies gradually making inroads in CAD, EDA, and other software segments [20][21]. Group 5: Communication Industry - The communication equipment sector has seen significant domestic market penetration, with leading companies like Huawei and ZTE holding substantial global market shares [26][28]. - The report emphasizes the potential for domestic substitution in core communication chips, particularly in the FPGA market, which is currently dominated by foreign firms [27][31]. Group 6: Pharmaceutical and Medical Industries - The scientific instruments sector is highlighted for its low domestic substitution rates, with significant opportunities for growth driven by supportive policies [33][34]. - The article points out the challenges in the production of borosilicate glass for pharmaceuticals, indicating a need for technological advancements to reduce reliance on imports [38][40].

| | | 深圳瑞华泰薄膜科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本季度转股情况：深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"） 向不特定对象发行可转换公司债券"瑞科转债"自 2023 年 2 月 24 日起可转换为 公司股份，自 2025 年 4 月 1 日至 2025 年 6 月 30 日期间，未有"瑞科转债"转 换为公司股票，转股数量为 0 股。 1 18 日至 2028 年 8 月 17 日。 累计转股情况：截至 2025 年 6 月 30 日，"瑞科转债"累计共有人民币 7,000 元已转换为公司股票，累计转股数量为 224 股，占"瑞科转债"转股前公 司已发行股份总额的 0.000124%。 未转股可转债情况：截至 2025 年 6 月 30 日，"瑞科转债"尚未转股的可 转债金额为人民币 429,993,000 元，占"瑞科转债"发行总量的 99.998372%。 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意深圳瑞华泰薄 ...

证券代码：688323 证券简称：瑞华泰 债券代码：118018 债券简称：瑞科转债 深圳瑞华泰薄膜科技股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024年度） 债券受托管理人 （深圳市罗湖区红岭中路 1012 号国信证券大厦 16-26 层） 二〇二五年六月 1 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、《深 圳瑞华泰薄膜科技股份有限公司（发行人）与国信证券股份有限公司（受托管理 人）签订的科创板向不特定对象发行可转换公司债券之受托管理协议》（以下简 称"《受托管理协议》"）、《深圳瑞华泰薄膜科技股份有限公司向不特定对象发 行可转换公司债券募集说明书》（以下简称"《募集说明书》"）、《深圳瑞华泰 薄膜科技股份有限公司 2024 年年度报告》等相关公开信息披露文件、第三方中 介机构出具的专业意见等，由本次债券受托管理人国信证券股份有限公司（以下 简称"国信证券"）编制。国信证券对本报告中所包含的从上述文件中引述内容 和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和完整性 做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项 ...